Current evidence does not support genotype-based training due to limited predictive value of genetic variants and lack of high-quality trials.
Do genotype-based training programs improve athletic performance?
Current evidence does not support the use of direct-to-consumer genetic tests to guide individualized athletic training protocols.
Absolute Event Rate: 0% vs 0%
Background: Sports genomics explores the genetic basis of athletic ability and trainability, gaining growing scientific and public interest. This has led to a surge in direct-to-consumer (DTC) genetic tests claiming to offer personalized training programs based on individual genotypes. However, a gap remains between these marketing claims and solid scientific validation. Purpose of Research: This systematic review evaluates the strength of association between specific genetic polymorphisms and athletic performance, and examines the scientific support for genotype-based training. Materials and Methods: Relevant literature was sourced from the PubMed database using keywords such as “genetics”, “athletic performance”, “genotype”, and “personalized training”. Results: Several studies reported associations between genetic variants and performance traits—most notably, ACTN3 with power and ACE with endurance. However, the predictive value for individuals remains limited. There is also a lack of high-quality randomized controlled trials (RCTs) testing genotype-based training programs. Existing trials often yield conflicting or inconclusive results. Conclusions: Current scientific evidence does not support the widespread adoption of genotype-based training. Although certain genes influence physical potential, athletic performance is a complex, polygenic trait shaped significantly by environmental and lifestyle factors. DTC genetic tests currently lack the robust validation required to guide individualized training protocols.
Demel et al. (Tue,) reported a other. Current evidence does not support genotype-based training due to limited predictive value of genetic variants and lack of high-quality trials.